Adjuvant chemotherapy for lymph node-negative, estrogen receptor-negative breast cancer: A tale of three trials

Journal of the National Cancer Institute

Volumn 96, Issue 24, 2004, Pages 1801-1804

  Albain, Kathy S ^a  

^a LOYOLA UNIVERSITY HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; HORMONE RECEPTOR; METHOTREXATE; PACLITAXEL; TAMOXIFEN;

AXILLARY LYMPH NODE; BREAST CANCER; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER RESEARCH; CANCER STAGING; CLINICAL TRIAL; EDITORIAL; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; MAMMOGRAPHY; NORTH AMERICA; POSTMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME; TREATMENT PLANNING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; LYMPHATIC METASTASIS; METHOTREXATE; ODDS RATIO; PROGNOSIS; RECEPTORS, ESTROGEN; SURVIVAL ANALYSIS;

EID: 11844257664     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/djh347     Document Type: Editorial

References (20)

1. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, et al. Cancer statistics, 2004. CA Cancer J Clin 2004;54:8-29.
2. Peto R. Mortality from breast cancer in the UK has decreased suddenly. BMJ 1998;317:476.
3. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 1998; 352:930-42.
4. Fisher B, Jeong J-H, Anderson S, Wolmark, N. Treatment of axillary lymph node-negative, estrogen receptor-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project clinical trials. J Natl Cancer Inst 2004;96:1823-31.
5. Fisher B, Redmond C, Dimitrov NV, Bowman D, Legault-Poisson S, Wickerham DL, et al. A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors. N Engl J Med 1989;320:473-8.
6. Mansour EG, Gray R, Shatila AH, Osborne CK, Tormey DC, Gilchrist KW, et al. Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer. An Intergroup study. N Engl J Med 1989;320:485-90.
7. Fisher B, Dignam J, Mamounas EP, Costantino JP, Wickerham DL, Redmond C, et al. Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate and fluorouracil. J Clin Oncol 1996;14:1982-92.
8. Fisher B, Anderson S, Tan-Chiu E, Wolmark N, Wickerham DL, Fisher ER, et al. Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23. J Clin Oncol 2001;19:931-42.
9. Albain K, Barlow W, O'Malley F, Siziopikou K, Yeh, I-T, Ravdin P, et al. for The Breast Cancer Intergroup of North America. Concurrent (CAFT) versus sequential (CAF-T) chemohormonal therapy (cyclophosphamide, doxorubicin, 5-fluorouracil, tamoxifen) versus T alone for postmenopausal, node-positive, estrogen and/or progesterone receptor-positive breast cancer: mature outcomes and new biologis correlates on phase III intergroup trial 0100 (SWOG-8814). Breast Cancer Res Treat (Proc San Antonio Breast Cancer Symp) 2004, In press. Abstract 37.
10. Fisher B, Redmond C, Legault-Poisson S, Dimitrov NV, Brown AM, Wickerham DL, et al. Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results form National Surgical Adjuvant Breast and Bowel Project B-16. J Clin Oncol 1990;8:1005-1018.
11. Bonetti M, Gelber RD. A graphical method to assess treatment-covariate interactions using the Cox model on subsets of the data. Stat Med 2000;19:2595-2609.
12. Singh R, Hellman S, Heimann R. The natural history of breast carcinoma in the elderly: implications for screening and treatment. Cancer 2004;100:1807-1813.
13. Hutchins L, Green S, Ravdin P, Lew D, Martino S, Abeloff M, et al. CMF versus CAF with and without tamoxifen in high-risk node-negative breast cancer patients and a natural history follow-up study in low-risk node-negative patients: first results of intergroup trial 0102. Proc ASCO 1998;17:1a.
14. Albain KS, Green SJ, Ravdin PM, Cobau CD, Levine EG, Ingle JN, et al. Adjuvant chemohormonal therapy for primary breast cancer should be sequential instead of concurrent: initial results from intergroup trial 0100 (SWOG-8814). Proc ASCO 2002;21:143.
15. Bear HD, Anderson S, Brown A, Smith R, Mamounas EP, Fisher B, et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project protocol B-27. J Clin Oncol 2003;21:4165-4174.
16. Citron ML, Berry DA, Cirrincione, C, Hudis C, Winer EP, Gradishar WJ, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of intergroup trial C9741/Cancer and Leukemia Group B trial 9741. J Clin Oncol 2003;21:1431-1439.
17. Ellis GK, Livingston RB, Gralow JR, Green SJ, Thompson T. Dose-dense anthracycline-based chemotherapy for node-positive breast cancer. J Clin Oncol 2002;20:3637-3643.
18. Henderson IG, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S, Ingle JN, et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003;21:976-983.
19. Levine MN, Bramwell VH, Pritchard KI, Norris BD, Shepherd LE, Abu-Zahra H, et al. Randomized trial of intensive cyclophosphamide, epirubicin and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate and fluorouracil in premenopausal women- with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1998;16:2651-2658.
20. Therasse P, Mauriac L, Welnicka-Jaskiewicz M, Bruning P, Cufer T, Bonnefoi H, et al. Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAKK multicenter study. J Clin Oncol 2003;21:843-850.